These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32083035)

  • 1. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
    Nada A; Abbasy M; Sabry A; Abdu Allah AM; Shehab-Eldeen S; Elnaidany N; Elimam H; Mohamed Ibraheem KI; Essa A
    Can J Gastroenterol Hepatol; 2020; 2020():1632959. PubMed ID: 32083035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.
    Strazzulla A; Coppolino G; Barreca GS; Gentile I; Rivoli L; Postorino MC; Mazzitelli M; Greco G; Costa C; Pisani V; Marascio N; Simeoni M; Focà A; Fuiano G; Foti D; Gulletta E; Torti C
    Clin Mol Hepatol; 2018 Jun; 24(2):151-162. PubMed ID: 29684978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
    Younas S; Mukhtar H; Gohar UF; Alsrhani A; Alzahrani B; Junaid K; Qamar MU; Ejaz H
    J Infect Dev Ctries; 2021 Oct; 15(10):1489-1496. PubMed ID: 34780372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
    Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
    Hussein HA; Allam AS; Moaty ASA
    Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
    Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
    Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Elsadek HM; Abdelbaser ES; Emara MH; Soliman HH; Farag AA
    Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1046-1053. PubMed ID: 33216478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
    Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
    Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    Chen YC; Li CH; Ko PH; Lee CC; Syu RJ; Tseng CW; Tseng KC
    PLoS One; 2021; 16(8):e0256505. PubMed ID: 34437608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
    Ahmed EI; Abdel Wahed WY; Hassan EA; Ahmed TI
    Curr Drug Saf; 2018; 13(3):187-195. PubMed ID: 30009714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Abdel-Moneim A; Aboud A; Abdel-Gabaar M; Zanaty MI; Ramadan M
    Hepatol Int; 2018 Jul; 12(4):348-355. PubMed ID: 29754329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
    Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.